Treatment of radiation nephropathy with ACE inhibitors and AII Type-1 and Type-2 receptor antagonists

Current Pharmaceutical Design

Volumn 13, Issue 13, 2007, Pages 1317-1325

  Moulder, J E ^a   Fish, B L ^a   Cohen, E P ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

ACE inhibitors; AII blockers; AII receptors; Angiotensin; Angiotensin II; Captopril; Chronic renal disease; Hypertension; Radiation injuries; Radiation nephropathy

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

BLOOD PRESSURE REGULATION; BONE MARROW TRANSPLANTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; MONOTHERAPY; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RADIATION DOSE; RADIATION INJURY; RECEPTOR BLOCKING; RENAL DIET; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT DURATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; KIDNEY DISEASES; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 34248381622     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780618821     Document Type: Review

References (72)

1. Luxton RW, Kunkler PB. Radiation nephritis. Acta Radiol Oncol 1964; 2: 169-78.
2. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995; 31: 1249-56.
3. Cohen EP, Moulder JE. In: Cohen EP Ed, Cancer and the Kidney. Oxford, Oxford University Press 2005; 169-79.
4. Cohen EP, Lawton CA, Moulder JE. Bone marrow transplant nephropathy: Radiation nephritis revisited. Nephron 1995; 70: 217-22.
5. Miralbell R, Bieri S, Mermillod B, Helg C, Sancho G, Pastoors B, et al. Renal toxicity after allogeneic bone marrow transplantation: The combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 1996; 14: 579-85.
6. Cohen EP, Moulder JE, Robbins MEC. Radiation nephropathy caused by Yttrium 90. Lancet 2001; 358: 1102-3.
7. Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA, et al. Renal toxicity after radionuclide therapy. Radiat Res 2004; 161: 607-11.
8. Moulder JE. Post-irradiation approaches to treatment of radiation injuries in the context of radiological terrorism and radiation accidents: a review. Int J Radiat Biol 2004; 80: 3-10.
9. Moulder JE, Cohen EP. Radiation-induced multi-organ involvement and failure: the contribution of radiation effects on the renal system. Br J Radiol Suppl 2005; 27: 82-8.
10. Robbins MEC, Bonsib SM. Radiation nephropathy: A review. Scanning Microsc 1995; 9: 535-60.
11. Cohen EP, Robbins MEC. Radiation nephropathy. Semin Nephrol 2003; 23: 486-99.
12. Rubin P, Casarett GW. In: Dalrymple GV, Gaulden ME, Kollmorgen GM, Vogel HH Eds, Medical Radiation Biology. Philadelphia, W.B. Saunders Company 1973; 160-89.
13. Moulder JE, Robbins MEC, Cohen EP, Hopewell JW, Ward WF. Pharmacologic modification of radiation-induced late normal tissue injury. Cancer Treat Res 1998; 93: 129-51.
14. Stone HB, McBride WH, Coleman CN. Modifying normal tissue damage post irradiation. Report of a workshop sponsored by the Radiation Protection Program, National Cancer Institute, Bethesda, Maryland September 6-8, 2000. Radiat Res 2002; 157: 204-23.
15. Cohen EP. Fibrosis causes progressive kidney failure. Med Hypotheses 1995; 45: 459-62.
16. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI workshop, December 3-4, 2003. Radiat Res 2004; 162: 711-28.
17. Withers HR, Mason KA, Thames HD. Late radiation response of kidney assayed by tubule cell survival. Br J Radiol 1986; 59: 587-95.
18. Sharma M, Sharma R, Ge XL, Fish BL, McCarthy ET, Savin VJ, et al. Early detection of radiation-induced glomerular injury by albumin permeability assay. Radiat Res 2001; 155: 474-80.
19. Sharma M, McCarthy ET, Sharma R, Fish BL, Savin VJ, Cohen EP, et al. Arachidonic acid metabolites mediate the radiation induced increase in glomerular albumin permeability. Exp Biol Med 2006; 231: 99-106.
20. Cohen EP, Fish BL, Moulder JE. The renin-angiotensin system in experimental radiation nephropathy. J Lab Clin Med 2002; 139: 251-7.
21. Moulder JE. Issues and updates: Report on an interagency workshop on the radiobiology of nuclear terrorism. Radiat Res 2002; 158: 118-24.
22. Augustine AD, Gondr-Lewis T, McBride W, Miller L, Pellmar TC, Rockwell S. Animal models for radiation injury, protection and therapy. Radiat Res 2005; 164: 100-9.
23. Moulder JE, Fish BL, Cohen EP. ACE inhibitors and AII receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr Pharm Des 2003; 9: 737-49.
24. Moulder JE, Fish BL, Cohen EP. Impact of angiotensin II type 2 receptor blockade on experimental radiation nephropathy. Radiat Res 2004; 161: 312-7.
25. Cohen EP, Fish BL, Moulder JE. Angiotensin II infusion exacerbates radiation nephropathy. J Lab Clin Med 1999; 134: 283-91.
26. Cohen EP. In: Davison AMA, Cameron JS, Grunfeld JP, Ponticelli C, Van Ypersele C, Ritz E, Winearls CG Eds, Oxford Textbook of Clinical Nephropathy. Oxford, Oxford University Press 2005; 1091-4.
27. Moulder JE, Fish BL. Late toxicity of total body irradiation with bone marrow transplantation in a rat model. Int J Radiat Oncol Biol Phys 1989; 16: 1501-9.
28. Robbins MEC, Campling D, Rezvani M, Golding SJ, Hopewell JW. Radiation nephropathy in mature pigs following the irradiation of both kidneys. Int J Radiat Biol 1989; 56: 83-98.
29. Prescott DM, Hoopes PJ, Thrall DE. Modification of radiation damage in the canine kidney by hyperthermia: a histologic and functional study. Radiat Res 1990; 124: 317-25.
30. Stewart FA, Luts A, Lebesque JV. The lack of long-term recovery and reirradiation tolerance in the mouse kidney. Int J Radiat Biol 1989; 56: 449-62.
31. Williams MV, Denekamp J. Sequential functional testing of radiation-induced renal damage in the mouse. Radiat Res 1983; 94: 305-17.
32. Liao ZX, Travis EL. Unilateral nephrectomy 24 hours after bilateral kidney irradiation reduces damage to the function and structure of the remaining kidney. Radiat Res 1994; 139: 290-9.
33. Cohen EP, Moulder JE, Fish BL, Hill P. Prophylaxis of experimental bone marrow transplant nephropathy. J Lab Clin Med 1994; 124: 371-80.
34. Lawton CA, Fish BL, Moulder JE. Effect of nephrotoxic drugs in the development of radiation nephropathy after bone marrow transplantation. Int J Radiat Oncol Biol Phys 1994; 28: 883-9.
35. Cohen EP, Fish BL, Moulder JE. Successful brief captopril treatment in radiation nephropathy. J Lab Clin Med 1997; 129: 536-47.
36. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors. Int J Radiat Oncol Biol Phys 1993; 27: 93-9.
37. Cohen EP, Molteni A, Hill P, Fish BL, Ward WF, Moulder JE, et al. Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab Invest 1996; 75: 349-60.
38. Greenberger JS, Weichselbaum RR, Cassady JR. In: Rieselbach RE, Garnick MB Eds, Cancer and the Kidney. Philadelphia, Lea & Febiger 1982; 814-23.
39. Cohen EP, Lawton CA, Moulder JE, Becker CG, Ash RC. Clinical course of late-onset bone marrow transplant nephropathy. Nephron 1993; 64: 626-35.
40. Paller MS. Bone marrow transplantation nephropathy. J Lab Clin Med 1994; 124: 315-7.
41. Molteni A, Moulder JE, Cohen EP, Fish BL, Taylor JM, Veno PA, et al. Prevention of radiation-induced nephropathy and fibrosis in a model of bone marrow transplant by an angiotensin II receptor blocker. Exp Biol Med 2001; 226: 1016-23.
42. Moulder JE, Fish BL, Cohen EP. Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiother Oncol 1998; 46: 307-15.
43. Cohen EP, Fish BL, Moulder JE. Treatment of radiation nephropathy with captopril. Radiat Res 1992; 132: 346-50.
44. Juncos LI, Carrasco Dueñas S, Cornejo JC, Broglia CA, Cejas H. Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron 1993; 64: 249-55.
45. Geraci JP, Sun MC, Mariano MS. Amelioration of radiation nephropathy in rats by postirradiation treatment with dexamethasone and/or captopril. Radiat Res 1995; 143: 58-68.
46. Moulder JE, Fish BL, Cohen EP, Bonsib SM. Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiat Res 1996; 146: 106-10.
47. Moulder JE, Fish BL, Cohen EP. Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. Int J Radiat Biol 1998; 73: 415-21.
48. Moser M. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. J Am Coll Cardiol 1997; 29: 1414-21.
49. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164-72.
50. Chung O, Unger T. Unopposed stimulation of the angiotensin AT2 receptor in the kidney. Nephrol Dial Transplant 1998; 13: 537-40.
51. Birkenhager WH, De Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999; 17: 873-81.
52. Siragy HM, De Gasparo M, El-Kersh M, Carey RM. Angiotensinconverting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001; 38: 183-6.
53. Siragy HM. AT1 and AT2 receptors in the kidney: role in disease and treatment. Am J Kidney Dis 2000; 36: S4-S9.
54. Bonnet F, Cao ZM, Cooper ME. Apoptosis and angiotensin II: Yet another renal regulatory system? Exp Nephrol 2001; 9: 295-300.
55. De Paepe B, Verstraeten VLRM, De Potter CR, Bullock GR. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol 2002; 117: 13-9.
56. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31: 349-55.
57. Siragy HM, Carey RM. Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2001; 10: 99-103.
58. Mifune M, Sasamura H, Shimizu-Hirota R, Miyazaki H, Saruta T. Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension 2000; 36: 845-50.
59. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin IIinduced hypertension. Circulation 2001; 104: 346-51.
60. Wolf G. 'The road not taken': role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant 2002; 17: 195-8.
61. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RAK, Thaiss F. Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors. Kidney Int 2002; 61: 1986-95.
62. 2 receptors. Am J Pathol 2001; 158: 1743-56.
63. Macari D, Bottari S, Whitebread S, De Gasparo M, Levens N. Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium-depleted rat. Eur J Pharmacol 1993; 249: 85-93.
64. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on rat vascular structure. J Clin Invest 1996; 98: 418-25.
65. Cohen EP. In: Dale DC, Federman DD Eds, ACP Medicine. New York, Web MD 2004.
66. Cohen EP, Hussain S, Moulder JE. Successful treatment of radiation nephropathy with angiotensin II blockade. Int J Radiat Oncol Biol Phys 2003; 55: 190-3.
67. Antignac C, Gubler MC, Leverger G, Broyer M, Habib R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 1989; 35: 1336-44.
68. Moulder JE, Fish BL, Cohen EP. Brief pharmacologic intervention in experimental radiation nephropathy. Radiat Res 1998; 150: 535-41.
69. Moulder JE, Fish BL, Cohen EP. Dietary sodium modification and experimental radiation nephropathy. Int J Radiat Biol 2002; 79: 903-11.
70. Gresh N. Development, validation, and applications of anisotropic polarizable molecular mechanics to study ligand and drug-receptor interactions. Curr Pharm Des 2006; 12(17): 2121-58.
71. Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005; 11(10): 1291-300.
72. Sagnella GA, Swift PA. The renal epithelial sodium channel: genetic heterogeneity and implications for the treatment of high blood pressure. Curr Pharm Des 2006; 12(18): 2221-34.